文献速递艾滋病与性传播感染

阿司匹林与阿托伐他汀对精英控制者和抗逆转录病毒治疗HIV感染者肠道菌群组成的影响评估

Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration.
PubMed 文献 · J Infect Dis · 2026-10-09

该研究分析了22例病毒学抑制的HIV感染者和12例精英控制者在随机接受阿司匹林或阿托伐他汀前及9个月后的肠道菌群。基线时两组菌群无差异;阿司匹林给药后β多样性显著变化,而阿托伐他汀后无差异。提示精英控制者肠道菌群类似病毒学抑制的HIV感染者,阿司匹林而非阿托伐他汀可能影响菌群多样性。

要点

  • 基线时精英控制者与病毒学抑制HIV感染者的肠道菌群无差异。
  • 阿司匹林给药后肠道菌群β多样性显著变化。
  • 阿托伐他汀给药后肠道菌群无显著变化。

核心结论

  • 精英控制者的肠道菌群与病毒学抑制的HIV感染者相似。
  • 阿司匹林而非阿托伐他汀可能影响HIV感染者的肠道菌群多样性。

研究设计与样本

  • 研究纳入22例病毒学抑制的HIV感染者和12例精英控制者,随机接受阿司匹林或阿托伐他汀,比较基线及9个月后肠道菌群。

主要发现

  • 基线时HIV感染者与精英控制者之间肠道菌群无差异。
  • 阿司匹林给药后β多样性显著变化,阿托伐他汀给药后菌群无差异。

临床怎么用

  • 对于病毒学抑制的HIV感染者,阿司匹林可能改变肠道菌群多样性,阿托伐他汀未见此影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gut dysbiosis is associated with chronic immune activation in people with HIV (PWH), but is not well-characterized in elite controllers (ECs) or PWH receiving aspirin or statins. We analyzed gut microbiota among 22 virally-suppressed PWH and 12 ECs before and 9-months after randomization to aspirin or atorvastatin. There were no differences in microbiota between PWH and EC at baseline. There was a significant change in beta diversity after aspirin administration, but no difference in microbiota after atorvastatin. These findings suggest that ECs have gut microbiota resembling virally-suppressed PWH, and aspirin but not atorvastatin may impact gut microbiota diversity in PWH.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Marotti M, Epling BP, Angelova A, et al. Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration. J Infect Dis. 2026. PMID: 42853985. doi:10.1093/infdis/jiag508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。